Allison Deangelis is a reporter for STAT, with a focus on covering various topics within the biotech industry. Her articles provide in-depth analysis and insights into the latest developments, trends, and key players in the field. Allison's work has also been featured in the Boston Globe Technology section.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Allison Deangelis focuses on the healthcare and pharmaceutical industry, particularly biotechnology. Her articles often include press releases, private sector announcements, data citations, and expert commentary.
To effectively reach out to Allison Deangelis, consider providing insights or access to individuals with expertise in cutting-edge biotechnological developments such as gene therapy, novel drug discoveries for conditions like obesity or cancer treatment. Pitches could also involve exclusive interviews with key figures in startups and established companies within the biotech space.
As Allison's geographic focus is not specified but her coverage seems international in nature due to its emphasis on major industry events and global players within the healthcare and pharmaceutical sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Adam Feuerstein, Elaine Chen, Allison DeAngelis
Why are pharmaceutical companies cutting more staff than cash-strapped biotechs? And who will Pfizer scout out as its next science chief?
By: Allison DeAngelis
By Allison DeAngelis July 16, 2024 C ardurion Pharmaceuticals, a startup that launched seven years ago with shelved cardiovascular drug candidates from Takeda Pharmaceuticals, has raised $260 million for a Series B round.
SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn't have worked.
By: Elaine Chen, Allison DeAngelis
By: Elaine Chen, Adam Feuerstein, Allison Deangelis
STAT's The Readout Loud covers an upcoming presentation from Summit Therapeutics, mixed data from Recursion, and amylin obesity drugs.
By: Allison DeAngelis
Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of its subsidiaries to pharma company Organon in a deal worth $1.2 billion.
By: Adam Feuerstein, Elaine Chen, Allison DeAngelis
By: Adam Feuerstein, Allison Deangelis
On STAT's podcast, hear about what’s in store for biotech VCs in 2025, Pfizer's new head of R&D, drug innovation in a second Trump term, and more.
(833) 317-6278 
